Alecensa was shown to reduce the risk of disease recurrence or death by 76% versus chemotherapy for patients with ALK-positive non-small cell lung cancer.
/PRNewswire/ LUNGevity Foundation, the nation s leading lung cancer-focused nonprofit organization, is proud to issue an RFA (Request for Application) for.
/PRNewswire/ LUNGevity Foundation, the nation s leading lung cancer-focused nonprofit organization, is pleased to issue an RFA (Request for Application) for.
LUNGevity and RETpositive Issue RFA for Pan-Cancer Research Focused on RET Biomarker streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ LUNGevity Foundation is honored to announce its partnership with the Rising Tide Foundation to issue an RFA (Request for Application) for the.